|

Semaglutide Pen Injector Clinical Trials

7 actively recruiting trials across 4 locations

No change since May 2026

Also known as: Ozempic, Wegovy, Wegovy®

Pipeline

Phase 2: 2Phase 3: 2Phase 4: 2Phase 1/2: 1

Top Sponsors

  • Yale University1
  • Virginia Commonwealth University1
  • University of Pennsylvania1
  • University of Colorado, Denver1
  • Universitaire Ziekenhuizen KU Leuven1

Indications

Other3 trials

Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
Phase 4
JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity
Phase 4
Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
Phase 3

Aurora, Colorado1 trial

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

University of Colorado Anschutz Medical Campus

Phase 3

New Haven, Connecticut1 trial

Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

Yale Pediatric Diabetes Center, Adult and Children's Progam

Phase 2

Philadelphia, Pennsylvania1 trial

Feasibility of Semaglutide in Advanced Lung Disease

University of Pennsylvania Perelman School of Medicine

Phase 1/2

Richmond, Virginia1 trial

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

Virginia Commonwealth University

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.